Cell line · CVCL_1923
EMT6
Cancer cell line, Mus musculus. Malignant neoplasms of the mouse mammary gland. 36 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. EMT6. Cell lines, record CVCL_1923. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1923
On this page
Cell line
As Cellosaurus gives it.
- Name
- EMT6
- Accession
- CVCL_1923
- RRID
- RRID:CVCL_1923
- Synonyms
- EMT-6, Experimental Mammary Tumour-6
- Species
- Mus musculus (Mouse)
- Sex
- Female
- Age at sampling
- Age unspecified
- Category
- Cancer cell line
- Diseases
- Malignant neoplasms of the mouse mammary gland (NCIt C21678)
- Derived from
- Mammary gland (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers36
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Intravenously deliverable oncolytic virus VET3-TGI favorably alters the tumor microenvironment. | J Immunother Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Collagen-Binding IL-15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self-Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Use Distinct Modes of Action to Induce Antitumor Immunity. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Microfluidic Nano-Assembly of Red-Blood-Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles. | Adv Healthc Mater | 2026 | Its Methods give the RRID and name the line | PubMed | |
| mTORC1 suppression by Trp53 mutation drives resistance to immune checkpoint blockade. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting KDM3B Elicits Anti-tumor Immunity by Alleviating SHP1-mediated STING Suppression in Triple-Negative Breast Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the Vim-PGI2 Pathway Enhances CD8+ T Cell-Mediated Antitumor Immunity in Breast Cancer. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PD-1 Blockade-Induced DKK1 Expression by CD8+ T Cells Promotes Blood-Brain Barrier Permeabilization. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 36
See all 36 papersRelatives9
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | EMT-6-1.1(1) | CVCL_4T81 | Cell lines | |
| Derived from it | EMT-6-1.1(2) | CVCL_4T82 | Cell lines | |
| Derived from it | EMT6-Fluc-Puro | CVCL_D5KE | Cell lines | |
| Derived from it | EMT6-LM2 | CVCL_RS43 | Cell lines | |
| Derived from it | EMT6-eGFP-Neo/Fluc-Puro | CVCL_D5KD | Cell lines | |
| Derived from it | EMT6-eGFP-Puro | CVCL_D5KC | Cell lines | |
| Derived from it | EMT6/P | CVCL_4173 | Cell lines | |
| Derived from it | EMT6/Ro | CVCL_C8D2 | Cell lines | |
| Derived from it | HyCyte EMT6 stable cell line for hNECTIN4 overexpression | CVCL_F4MQ | Cell lines |
Cell banks4
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-2755 | ATCC | |
| CLS | 305159 | CLS | |
| Hysigen | TCM-C728 | Hysigen | |
| NCI-DCTD | EMT-6 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1923
GET https://conductscience.org/api/cell-lines/v1/CVCL_1923/papers?page=2